aTyr Pharma, Inc. (NASDAQ:LIFE) shares were trading at the highest level since 2018, hitting the daily high of $12.97 today morning.

The reason is that the company presented top-line data from its Phase 1b/2a double-blind, placebo-controlled clinical trial of ATYR1923 in 37 patients with pulmonary sarcoidosis. The data surpassed the expectations, demonstrating a dose dependent improvement in such diverse efficacy measurements as steroid sparing (reduction), Forced Vital Capacity (FVC), clinical/QOL measurements like dyspnea, cough, etc., and inflammatory biomarker reductions; all this with little change in the safety profile of the drug.